Viewing Study NCT02263495


Ignite Creation Date: 2025-12-24 @ 1:59 PM
Ignite Modification Date: 2026-02-02 @ 6:35 PM
Study NCT ID: NCT02263495
Status: COMPLETED
Last Update Posted: 2020-07-14
First Post: 2014-10-06
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Eribulin Plus Gemcitabine (EG) vs Paclitaxel Plus Gemcitabine (PG) in HER2-Negative Metastatic Breast Cancer
Sponsor: Asan Medical Center
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Metastatic Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None HER2-Negative View